All the news Showing 10 of 59 articles from: Injecting drug useGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Hepatitis C rates in US track the opioid epidemic Liz Highleyman / 14 December 2018 Nearly 2.4 million people in the United States are living with active hepatitis C virus (HCV) infection, according to the latest data from the US Centers for Disease Control and Prevention (CDC). ... Australian experience shows high DAA uptake and rapid fall in rates of HCV viraemia among people who inject drugs Michael Carter / 26 November 2018 Providing hepatitis C virus (HCV) therapy with direct-acting antivirals (DAAs) to people who inject drugs can achieve rapid reductions in community prevalence of viraemia, according to Australian research published in the Journal of Hepatology. ... Majority of US young adults who use drugs are not tested for hepatitis C or HIV Liz Highleyman / 16 October 2018 Only about a third of adolescents and young adults diagnosed with opioid use disorder in the United States are screened for hepatitis C virus (HCV) or HIV, even though injection drug use is ... Low dead-space syringes associated with lower hepatitis C prevalence in people who inject drugs Keith Alcorn / 01 October 2018 Exclusive use of low dead-space syringes is associated with a lower prevalence of hepatitis C virus (HCV) in people who inject drugs, especially in people who began injecting drugs recently, a study ... Reinfection risk after hepatitis C treatment higher in recent drug users Keith Alcorn / 07 September 2018 Reinfection with hepatitis C after successful treatment is more common in younger people who inject drugs and recent and former drug users are at greatest risk of reinfection, a cohort study in ... Supervised drug consumption sites offer opportunities for HCV testing and treatment Liz Highleyman / 02 August 2018 Most supervised drug consumption facilities offer hepatitis C virus (HCV) testing and referrals, but very few offer treatment, indicating that they could potentially play a greater role in curbing transmission and negative health ... Scotland’s reduction in new HCV infections due to harm reduction, not treatment Keith Alcorn / 12 June 2018 The reduction in new hepatitis C virus (HCV) infections that has taken place in Scotland since 2008 is most likely due to increased provision of needle and syringe programmes and ... Harm reduction measures for HCV prevention and treatment lacking in Europe's prisons, survey finds Keith Alcorn / 31 May 2018 Harm reduction measures for the prevention and treatment of hepatitis C in prisoners are still lacking in the majority of European countries and the lack of harm reduction will block ... Eight weeks of treatment with Epclusa cured almost all people with HCV receiving opioid substitution therapy Keith Alcorn / 12 April 2018 An eight-week course of sofosbuvir/velpatasvir (Epclusa) cured almost all people with hepatitis C genotype 3 without cirrhosis receiving treatment alongside opioid substitution therapy through community pharmacies or prisons in the Greater Glasgow area, ... Harm reduction scale-up needed to eliminate HCV in people who inject drugs, European model predicts Keith Alcorn / 01 February 2018 Elimination of hepatitis C among people who inject drugs in Europe will require simultaneous scale-up of direct-acting antiviral treatment, needle and syringe programmes (NSP) and opioid substitution therapy (OST), and ... ← Prev12345...6Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Transfusion and medical procedures Injecting drug use Mother to child Sexual transmission Non-medical blood transfer HBV vaccination Epidemiology Screening and testing policy Health services, policy and advocacy Social issues Conference news Email bulletin archive